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Abstract. Endometrial cancer is the most common female 
reproductive cancer in the United States and is associated with 
deregulated tight junction protein expression. Given the highly 
estrogen-responsive nature of this tissue, we investigated the 
effects of estrogen and its agonist, 4-OH TAM, on the expres-
sion and subcellular localization of the tight junction protein 
claudin-4 (CLDN-4), in HEC-1A endometrial cancer cells. In 
untreated HEC-1A cells, we observed dramatic overexpres-
sion of claudin-4 protein. In addition, differential detergent 
extraction analysis indicated that claudin-4 was localized 
primarily in the membrane but also found in the cytosolic, 
nuclear and cytoskeletal fractions. Upon exposure of HEC-1A 
to estradiol (E2), we observed a biphasic effect both on the 
overall expression of claudin-4 protein and on its cytosolic and 
cytoskeletal presence as demonstrated by immunoblot analysis. 
Immunofluorescence analysis also revealed a biphasic effect 
of E2 on claudin-4 expression. In contrast, we observed no 
changes in expression levels nor in the subcellular distribution 
patterns of claudin-4 in HEC-1A cells treated with different 
concentrations of 4-OH TAM. The intracellular presence of 
CLDN-4 coupled with the biphasic effects of E2 on CLDN-4 
expression in the cytoskeleton suggest that this protein may be 
involved in cell signaling to and from TJs. 
Introduction
According to the American Cancer Society (1), endometrial 
cancer is the most common female reproductive cancer in the 
United States with an incidence of 1 in 37 women. The effects 
of estradiol (E2) on reproductive tract structure and function are 
well known. Recently, however, studies have indicated a role 
for E2 in tumor initiation and progression through its promo-
tion of the proliferative, migratory and invasive capabilities of 
cells (2-6). Many of the changes that occur in the endometrium 
during tumorigenesis are similar to those observed during 
implantation. For example, both processes exhibit diminished 
endometrial cell to cell attachment through destabilization of 
tight junctions (TJs), expression of matrix metalloproteinases, 
differential expression of integrins and angiogenesis (7).
TJs consist of a complex of proteins located on the apical 
side of cells and are important for regulating paracellular 
transport and maintaining cell polarity (8). Furthermore, TJs 
are essential for the tight sealing of cellular sheets necessary to 
preserve the structural integrity of tissues and organs. Recent 
studies also suggest a role for TJ proteins in recruiting signaling 
proteins that regulate processes such as gene transcription, 
cellular proliferation, differentiation and morphogenesis (8). 
The TJ protein complex consists of three types of integral 
membrane proteins; claudins (CLDNs), occludin and junctional 
adhesion molecules (JAMs). Claudins are the predominant 
molecular component of TJs and are essential both for their 
assembly and function (8,9). CLDNs belong to a 24-member 
protein family that display distinctive tissue-specific expres-
sion and are involved in multiple normal cellular processes. In 
addition, alterations in CLDN gene expression or changes in 
subcellular localization have been shown to be associated with 
tumor progression (10).
Specifically, increases in CLDN-3 and -4 expression have 
been observed in uterine serous papillary carcinoma (11,12), 
clear-cell endometrial carcinoma (11) and uterine carcinosar-
coma (13). Notably, overexpression of CLDN-3 and -4 was 
associated with a poor clinical outcome (12). Endometrioid 
adenocarcinomas expressing particularly high levels of 
claudin-3 and -4 proteins have been found by electron 
microscopy to exhibit morphologically disrupted TJs (10). 
Consistent with these findings, overexpression of these two 
claudin proteins has been positively correlated with tumor 
progression in the endometrium and increased myometrial 
invasion (10). In contrast to the overexpression of claudin-3 
and -4 observed in endometrial cancer, endometriosis appears 
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to be associated with a decrease in the levels of these two 
proteins (13,14).
The reason for the upregulation of claudin-3 and -4 in 
certain endometrial tumors is currently unclear but given its 
role in the physiology of the endometrium, it is possible that E2 
may be involved. Whereas two previous studies have shown that 
exposure of MCF-7 breast cancer cells to low concentrations 
of E2 results in a decrease in claudin-4 gene expression (15,16), 
there are very few published studies demonstrating the effects 
of E2 on claudin expression in endometrial cancer cells. In the 
current study, therefore, we investigated the effects of varying 
E2 concentrations on the expression and subcellular localiza-
tion of CLDN-4.
Materials and methods
Cell lines and tissue culture conditions. The endometrial 
cancer call line HEC-1A was obtained from ATCC (Manasas, 
vA, USA) and cultured in McCoys 5A supplemented with 10% 
fetal bovine serum (FbS) and 1% penicillin/streptomycin/2 mm 
L-glutamine (pSG) purchased from Life Technologies. Cells 
were maintained at 37˚C in a 5% CO2 atmosphere.
Compounds. The compounds estradiol (E2) and 4-hydroxy-
tamoxifen (4-OH TAM) were purchased from Sigma and 
dissolved in 100% ethanol, stored, and protected from light in 
stock solutions of 1 mM at -20˚C. The final concentration of 
ethanol in culture media was always <0.1% (v/v).
E2 and 4-OH tamoxifen exposure experiment. Cells were 
plated (2x105 cells/well) into 6-well plates or seeded 
(1x106 cells) onto 25 cm2 culture flask and cultured with their 
respective media supplemented with 10%FbS-1% pSG for 
48 h. Logarithmic phase cells were washed twice with pbS 
and cells were serum starved for 24 h before the medium 
was replaced with 10% charcoal treated fetal bovine serum 
(CSFbS) (HyClone) with different concentrations of E2 
or 4-OH TAM ranging from 0-100 nM. The medium was 
replaced daily to ensure constant hormone concentration. 
Cells were harvested after 48 h to prepare whole cells protein 
extracts or subcellular fractions.
Subcellular fractionation. HEC-1A cells were treated with 
a series of commercial extraction buffers (Calbiochem) 
according to manufactures instructions to obtain cytosolic, 
membranous, nuclear and cytoskeletal fractions.
Western blot analysis. proteins in whole cell extracts and 
subcellular fractions were suspended in 4X sample buffer 
(40% v/v glycerol, 4% SDS, 0.5% w/v bromophenol blue, 
10% β-mercaptoethanol and 0.16 M Tris, pH 7.0), subjected 
to electrophoresis on precast 12% SDS-polyacrylamide gels 
and electrophoretically transferred to Immobilon-p pvDF. 
The membranes were probed for 1 h at room temperature with 
2 µg/ml rabbit polyclonal claudin-3, 3 µg/ml mouse monoclonal 
claudin-4 (Life Technologies) or 1 µg/ml of rabbit anti-actin 
(I-19) (Santa Cruz biotechnology, Santa Cruz, CA, USA) 
primary antibodies in 5% milk/pbS solution. Subsequently, 
the membranes were incubated with 1:3000 horseradish 
peroxidase-conjugated secondary antibody (goat anti-rabbit or 
goat-anti mouse; IgG; bio-Rad Laboratories) for 1 h at room 
temperature. For signal detection the enhanced chemilumines-
cence ECL-plus kit (Amersham, buckinghamshire, Uk) was 
used according to manufacturer's instructions.
Confocal microscopy. Untreated or hormone treated log phase 
cells were harvested and plated at 5x105 cells per chambered 
coverslide (Lab-Tek, Fisher Scientific) and grown at 37˚C until 
80% confluency. Cells were then rinsed with pre-cooled PBS 
three times and fixed in pre-cooled 95% ethanol for 30 min 
on ice. Following rehydration in pbS slides were blocked with 
3% bSA, 0.05% saponin in pbS. Claudin-4 anti-sera (1:250) 
(Life Technologies) was applied overnight at 4˚C, followed by 
three wash cycles with pbS-saponin and incubation with goat 
anti-mouse-IgG conjugated to Rhodamine Red-X (Jackson 
ImmunoResearch) for 1 h at room temperature. Nuclei were 
counterstained with Hoechst 33342 (1:1000) and filamentous 
actin stained with Alexa 647-phalloidin (1:500) followed 
by pbS washing and treatment with prolong Gold antiFade 
Reagent (Life Technologies). High-resolution 1024X1024 
images were collected using a Nikon A1R confocal system 
with the 40X plan Fluor NA 1.4 oil objective. The images 
were thresholded, normalized and maximum intensity projec-
tions from 8 µm z-stacks were collected. Fluorescent image 
intensity was quantified and presented as the mean ± SEM. 
Significantly different groups were determined by ANOVA 
with Tukey's HSD analysis (p<0.05).
Results
Claudin-4 expression in normal human tissues and repro-
ductive cancer cell lines. To determine the variation of 
expression of CLDN-4 in normal tissues, we analyzed a 
panel of protein extracts derived from human bladder, breast, 
cervix, kidney, ovary, placenta, prostate, testis and uterus 
(pre-made tissue western blot purchased from proSci). As 
seen in Fig. 1 the strongest expression of CLDN-4 was seen 
in the placenta, followed by the bladder, cervix and kidney. A 
very faint signal was observed in prostate and breast tissue. 
There was no obvious expression of CLDN-4 in the uterus, 
ovary and testis.
In contrast to the low expression of CLDN-4 in normal 
uterine tissue (Fig. 1), the endometrial adenocarcinoma cell 
line HEC-1A, showed robust expression of CLDN-3 and -4 
(Fig. 2). A less intense CLDN-4 signal was observed in the 
endometrial cancer cell line RL95-2. There was no detect-
able signal in the cancer cell lines HEC-1b (endometrial), 
HeLa (cervical) and Sk-Ov-3 (ovarian). Similarly, there 
were non-detectable to low levels of CLDN-3 in all but the 
HEC-1A cancer cells. These data indicate that the CLDN-3 
and CLDN-4 proteins are abnormally overexpressed in the 
HEC-1A cell line (Fig. 2). In summary, these data show 
differential expression patterns of CLDN-3 and -4 between 
the different cancer cell lines.
Subcellular localization of claudin-4 protein. We used 
differential detergent cell fractionation, to assess the subcel-
lular localization of CLDN-4 in HEC-1A cells. As shown in 
Fig. 3, we observed CLDN-4 expression in all four sub cellular 
fractions, cytosolic (C), membranous (M), nuclear (N) and 
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cytoskeletal (Csk). The most intense signals were in the 
membranous and cytoskeletal fractions.
Effects of E2 on CLDN-4 expression and subcellular local-
ization. Cells were serum-starved for 24 h then exposed to 
10-100 nM E2/CSFbS for 48 h. The medium was replaced daily 
to ensure constant hormone concentration. As a control, one 
set of cells was grown in FbS-containing medium. Whole cell 
protein extracts (Fig. 4A) and subcellular fractions (Fig. 4b) 
were subsequently analyzed for CLDN-4 expression by immu-
noblot analysis. As shown in Fig. 4A, E2 effected CLDN-4 
expression in a biphasic manner with the most intense signal 
observed at 50 nM E2. In addition, we observed alterations in 
the pattern of CLDN-4 subcellular distribution in response 
to different E2 concentrations. Regardless of the E2 concen-
tration, CLDN-4 expression was predominantly observed in 
the membrane fraction (Fig. 4b). We observed evidence of a 
biphasic E2 effect on both the cytosolic and cytoskeletal pres-
ence of CLDN-4 in HEC-1A cells. Specifically, there was a 
high level of CLDN-4 in cells treated with 0, 10 and 100 nm 
E2 with barely detectable levels in cells treated with 50 nM 
E2. Furthermore, high levels of CLDN-4 were observed in the 
cytoskeletal fractions of cells treated with 10 nM but not in 
those cells treated with 0 nM and 50 nM E2.
Effects of 4-OH tamoxifen on CLDN-4 expression and 
sub cellular localization. We evaluated the expression of 
CLDN-4 in response to various 4-OH TAM concentrations 
(0-100 nM) and found it to be concentration-independent 
Figure 1. Claudin-4 (CLDN-4) expression in a panel of normal human tissues. A pre-made western blot (proSci) containing a panel of protein extracts derived 
from different human tissues was probed with anti-claudin-4. The strongest expression of CLDN-4 was seen in the placenta, followed by bladder, cervix and 
kidney, A very faint signal was observed in prostate and breast. There was no detectable expression of CLDN-4 in the uterus, ovary and testis.
Figure 2. Overexpression of claudin (CLDN)-3 and -4 in the endometrial 
cancer cell line HEC-1A. A panel of female reproductive cancer cell lines 
was subjected to immunoblot analysis using antibodies to claudin-3, -4 and 
actin. Overexpression of CLDN-3 and -4 was observed in the endometrial 
adenocarcinoma cell line HEC-1A relative to cervical (HeLa), ovarian 
(Sk-Ov-3) and the endometrial (RL95-2 and HEC-1b) cancer cell lines.
Figure 3. Subcellular localization of claudin-4 (CLDN-4) in HEC-1A cells 
by differential detergent fractionation. Immunoblots containing subcellular 
fractions of HEC-1A cells were probed with anti-CLDN-4. The majority of 
CLDN-4 was localized in the membrane fraction (M) and cytoskeletal (Csk) 
fractions with readily detectable signal in both the nuclear (N) and cytosolic 
(C) fractions. The blot is representative of 3 separate experiments.
Figure 4. biphasic effect of estradiol on claudin-4 (CLDN-4) expression in 
HEC-1A cells. Cells were exposed to a range of estradiol concentrations 
(0-100 nM) in CSFbS for 72 h. As a control, one set of cells was grown 
in media containing FbS. Whole cell protein extracts (A) and four cellular 
subfractions (b) cytosolic (C), membranous (M), nuclear (N), and cytoskel-
etal (Csk) were subsequently analyzed for CLDN-4 (~22 kDa) expression 
by immunoblot analyis. Actin was used as a loading control. Estradiol 
increased CLDN-4 expression with a biphasic effect seen at the two highest 
concentrations. We observed alterations in the pattern of CLDN-4 subcel-
lular distribution in response to different estradiol concentrations. The blot is 
representative of 3 separate experiments.
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(Fig. 5A). Similarly, the subcellular distribution pattern of 
CLDN-4 was also 4-OH TAM-independent. Specifically, we 
observed the most intense CLDN-4 signal in the membranous 
fraction closely followed by the cytosolic fraction (Fig. 5b). 
Readily detectable bands were also observed in the cytoskel-
etal fraction of the cells exposed to 10-100 nM 4-OH TAM. 
However, only barely detectable levels of CLDN-4 were 
observed in the nuclear fractions at all concentrations.
Effects of E2 on CLDN-4 expression and localization by 
immunofluorescence. CLDN-4 localization was evaluated by 
indirect immunofluorescence using laser scanning confocal 
microscopy. E2 supplementation (Fig. 6A) enhanced CLDN-4 
expression and localization at cell-cell contacts. HEC-1A 
cells cultured in the absence of E2 expressed modest levels 
of CLDN-4 with localization distributed between the cyto-
plasm and membrane. E2 (10 nM) resulted in a shift toward 
membrane localization with a slight elevation in expression. 
Robust elevation of CLDN-4 signal occurred with 50 nM E2 
supplementation as indicated by clearly delineated cell-cell 
contacts and a marked elevation in intensity. CLDN-4 signal 
was apparent in HEC-1A cells treated with 100 nM E2 but the 
junctional intensity was diminished and intracellular signal 
more frequent. Quantitation of CLDN-4 fluorescent intensity 
is presented in Fig. 6b with significant differences found 
between each E2 treatment group. HEC-1A cells cultured in 
defined media with FBS exhibited CLDN-4 specific staining 
at the perijunctional actin ring (Fig. 6C). The junctional inten-
sity of CLDN-4 from cells cultured in media with FbS was 
statistically undistinguishable from cells cultured in 100 nM 
E2 (Fig. 6b).
Discussion
There is a growing body of evidence suggesting that altera-
tions in CLDN expression may be involved in the progression 
of some cancers (17) such as endometrial carcinoma (11). 
However, the regulation of these changes in expression are 
not well understood. Thus, the current study sought to inves-
tigate the potential role of E2 and the chemotherapeutic drug, 
4-OH TAM, on CLDN-4 expression in the endometrial cancer 
cell line HEC-1A.
Our findings show that whereas CLDN-4 is either not 
expressed or barely expressed in the endometrial cell lines 
HEC-1b and RL95-2, respectively, it is dramatically over-
expressed in HEC-1A cancer cells. Furthermore, CLDN-3 
was also overexpressed in HEC-1A relative to the other 
two endometrial cancer cell lines. Notably, there was no 
detectable CLDN-4 expression in the normal uterine tissue. 
These findings are consistent with previous studies that have 
demonstrated elevated CLDN-4 expression with increased 
endometrial tumor grade (10-12). In addition, the observed lack 
of CLDN-4 expression in normal uterine tissue agrees with 
previous studies that demonstrated absent or weak CLDN-4 
expression in normal endometrial cells (NEC), proliferative 
and secretory endometrial tissue (10,11). 
Currently, the regulation of CLDN-4 expression in endo-
metrial cells is not well understood. Owing to its major role 
in the endometrium, we investigated the possible effects 
of E2 and 4-OH TAM, a known E2 partial agonist in the 
endometrium, on the expression of CLDN-4. Notably, we 
observed a clear biphasic effect of E2 on CLDN-4 expres-
sion. The lowest levels of expression were seen at 10 nM 
and 100 nM E2 whereas the level of CLDN-4 expression 
increased following exposure to 50 nM E2 as demonstrated by 
both immunoblot and immunofluorescent analyses. Similar 
to our findings, Gadal et al (16) also observed a decrease in 
CLDN-4 gene expression in MCF-7 breast cancer cells upon 
exposure to 10 nM E2. In contrast, Someya et al (18) showed 
a dose-dependent increase in CLDN-4 protein expression in 
the Sawano uterine cancer cell line with the highest levels of 
expression observed at 100 µM. It should be noted, however, 
that the concentrations of E2 used in the latter study are above 
the normal physiological range.
Whereas we and others have shown a biphasic effect of E2 
in endometrial and breast cancer cells, Zeng et al (19) did not 
observe an E2 biphasic effect on CLDN-4 expression in human 
cervical cells. This discrepancy is likely attributable to inherent 
differences between the two tissue types studied. In addition to 
CLDN-4, E2 has been shown to have a biphasic effect on the 
levels of another tight junction protein, occludin, in both human 
vascular epithelial cells (20) and cervical cells (19).
As a complement to the above E2 exposure studies we 
treated the HEC-1A cells with the endometrial estrogen 
agonist, 4-OH TAM. Decreased CLDN-4 expression occurred 
only at concentrations of 100 nM 4-OH TAM. Owing to the 
differential effects of 4-OH TAM on endometrial and breast 
tissues, it is not surprising that Gadal et al (16) observed an 
increase in CLDN-4 gene expression following treatment of 
MCF-7 breast cancer cells with 100 nM 4-OH TAM.
We next determined the effect of E2 on the subcellular 
localization of CLDN-4 in HEC-1A cells. Using differential 
Figure 5. Induction of claudin-4 (CLDN-4) expression by 4-OH tamoxifen 
(4-OH TAM) in HEC-1A cells. Cells were exposed to a range of 4-OH TAM 
concentrations (0-100 nM) in CSFbS for 72 h. As a control, one set of cells 
was grown in media containing FbS. Whole cell protein extracts (A) and 
four cellular subfractions (b) cytosolic (C), membranous (M), nuclear (N) 
and cytoskeletal (Csk) were subsequently analyzed for CLDN-4 (~22 kDa) 
expression on immunoblots. Actin was used as a loading control. Non-dose 
dependent induction of claudin-4 expression by 4-OH TAM was observed. 
However, the effect was not biphasic in nature. No dramatic alterations in 
the pattern of CLDN-4 subcellular distribution were observed in response 
to different 4-OH TAM concentrations with the exception of a modest dose-
dependent increase in signal in the nuclear fraction. blot is representative of 
3 separate experiments.
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detergent extraction analysis, we observed CLDN-4 in all 
four subcellular fractions, membranous, cytosolic, nuclear 
and cytoskeletal. Specifically, high levels of CLDN-4 were 
observed in the nuclear fraction at the highest E2 concen-
tration (100 nM). This contrasts with the barely detectable 
nuclear fraction-specific signal at all other concentrations 
(0-50 nM). In addition, we observed a biphasic effect of E2 on 
CLDN-4 expression in the cytoskeletal fraction of HEC-1A 
cells. Immunofluorescence analysis also showed a biphasic 
effect of E2 on the expression of claudin-4 with a shift to 
an intracellular localization of claudin-4 with increasing E2 
concentration.
Whereas the expression of CLDN-4 in the membrane is 
expected as a part of its role in the TJ, the significance of the 
intracellular localization is not clear. previous studies have 
reported delocalization of CLDN proteins. For example, 
Zhu et al (20) observed the presence of CLDN-1, -3, and -4 
in the cytoplasm of cells from ovarian epithelial tumors by 
Figure 6. E2-induced intracellular redistribution of claudin-4 (CLDN-4) in HEC-1A cells. Cells were cultured onto chambered coverslides and treated with 
0-100 nM E2. Representative maximum intensity projection images are presented in (A) following CLDN-4 indirect immunofluorescence. Fluorescent image 
intensity was quantified and presented as the mean ± SEM (B). Letters indicate significantly different groups as determined by ANOVA with Tukey's HSD 
analysis (p<0.05). (C) Representation of HEC-1A cells cultured in media with FbS. A composite image is presented in addition to the individual channels. 
Junctional CLDN-4 corresponds to perijunctional F-actin localization. Nuclei were counterstained with Hoechst 33342 and filamentous actin was labeled with 
Alexa 647 phallodin. Scale bar, 50 µm.
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immunofluorescence analysis. Furthermore, Leotlela et al (21) 
found that CLDN-1 was expressed almost exclusively in the 
nucleus of benign nevi, or birthmarks, whereas it was located 
in the cytosolic and membranous fractions in highly metasta-
stic melanoma cells. Lejeune et al (22) showed that the shift 
of CLDN-4 from the membrane to the cytoskeleton upon 
exposure of T84 human colonic cells to the host inflamma-
tory mediator prostaglandin E2 correlates with dissociation of 
CLDN-4 from the TJ and is possibly responsible for the rapid 
changes in TER that they subsequently observed.
phosphorylation of CLDN proteins also appears to play 
a role in their subcellular localization. D'Souza et al (23) 
demonstrated that the phosphorylation of CLDN-3 on a 
threonine residue alters the localization of this protein within 
the membrane and the cytoplasm of ovarian OvCA433 
cancer cells. Similarly, phosphorylation of CLDN-4 in HT29 
colorectal adenocarcinoma cells weakens the association 
between CLDN-4 and ZO-1, leading to an increased presence 
of CLDN-4 in the cytoplasm (24). Furthermore, research has 
shown that phosphorylation of CLDN-1 in human melanoma 
cells can result in the redistribution of CLDN-1 to the nucleus 
or cytoplasm (25).
Our findings underscore the dynamic nature of the TJ 
as evidenced by the changes in subcellular localization of 
CLDN-4 upon exposure to E2. Just how these changes in 
subcellular localization come about is unclear. However, it 
has been shown that CLDNs can be removed from the plasma 
membrane by endocytosis into cytoplasmic vesicles (26) 
and they have been found in extracellular exosomes of 
cancer tissues (27). However, endocytosis and exocytosis 
do not explain how an integral membrane protein, with four 
hydrophobic (27) domains, can dissolve in the cytosol and 
translocate to the nucleus despite the absence of a nuclear 
localization sequence (28). The delocalization of CLDNs may 
indicate a role for CLDN proteins in cell signaling pathways 
with the pDZ domain of CLDNs providing a promising site for 
the formation of signaling complexes (29).
Due to their frequent overexpression in numerous cancers 
and function as receptors for Clostridium perfringens 
enterotoxin (CpE), CLDN-3 and -4 have been considered as 
useful targets in treating tumors overexpressing one or both 
proteins, such as uterine serous papillary carcinoma (30). 
To prevent wide-spread cytolysis by use of this therapy, 
researchers have focused on a non-cytotoxic C-terminal frag-
ment of CPE to specifically bind CLDN-3 or -4, altering the 
TJ, and subsequently allowing for better drug absorption by 
affected cells (31). Furthermore, the changes in CLDN-3 and 
-4 expression in certain cancers have suggested that these 
proteins may be potential prognostic markers. Indeed, a recent 
study developed a so-called CURIO score based on CLDN-4 
and E-cadherin expression in breast cancer. This score has 
proven generally accurate in predicting a poorer prognosis 
for those patients whose breast tumors overexpress these two 
proteins (32).
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